These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 28650323)
1. The naphthoquinone plumbagin suppresses ADP-induced rat platelet aggregation through P2Y1-PLC signaling pathway. Zhang Q; Liao X; Wu F Pak J Pharm Sci; 2017 Mar; 30(2(Suppl.)):573-578. PubMed ID: 28650323 [TBL] [Abstract][Full Text] [Related]
2. Potassium 2-(1-hydroxypentyl)-benzoate inhibits ADP-induced rat platelet aggregation through P2Y1-PLC signaling pathways. Yang H; Xu S; Li J; Wang L; Wang X Naunyn Schmiedebergs Arch Pharmacol; 2015 Sep; 388(9):983-90. PubMed ID: 25787305 [TBL] [Abstract][Full Text] [Related]
3. Effect of clopidogrel administration to healthy volunteers on platelet phosphorylation events triggered by ADP. Contreres JO; Dupuy E; Job B; Habib A; Bryckaert M; Rosa JP; Simoneau G; Herbert JM; Savi P; Levy-Toledano S Br J Haematol; 2003 Feb; 120(4):633-42. PubMed ID: 12588350 [TBL] [Abstract][Full Text] [Related]
4. The role of adenosine diphosphate mediated platelet responsiveness for the stability of platelet integrity in citrated whole blood under ex vivo conditions. Koessler J; Schwarz M; Weber K; Etzel J; Koessler A; Boeck M; Kobsar A PLoS One; 2017; 12(11):e0188193. PubMed ID: 29155852 [TBL] [Abstract][Full Text] [Related]
5. Benzoyl ATP is an antagonist of rat and human P2Y1 receptors and of platelet aggregation. Vigne P; Hechler B; Gachet C; Breittmayer JP; Frelin C Biochem Biophys Res Commun; 1999 Mar; 256(1):94-7. PubMed ID: 10066429 [TBL] [Abstract][Full Text] [Related]
6. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Hechler B; Eckly A; Ohlmann P; Cazenave JP; Gachet C Br J Haematol; 1998 Dec; 103(3):858-66. PubMed ID: 9858246 [TBL] [Abstract][Full Text] [Related]
7. Diverse signalling of the platelet P2Y Amison RT; Jamshidi S; Rahman KM; Page CP; Pitchford SC Eur J Pharmacol; 2018 May; 827():58-70. PubMed ID: 29534999 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Baurand A; Raboisson P; Freund M; Léon C; Cazenave JP; Bourguignon JJ; Gachet C Eur J Pharmacol; 2001 Feb; 412(3):213-21. PubMed ID: 11166284 [TBL] [Abstract][Full Text] [Related]
9. Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: phosphate substitution leads to multiple pathways of inhibition of platelet aggregation. Xu B; Stephens A; Kirschenheuter G; Greslin AF; Cheng X; Sennelo J; Cattaneo M; Zighetti ML; Chen A; Kim SA; Kim HS; Bischofberger N; Cook G; Jacobson KA J Med Chem; 2002 Dec; 45(26):5694-709. PubMed ID: 12477353 [TBL] [Abstract][Full Text] [Related]
10. The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. Hechler B; Léon C; Vial C; Vigne P; Frelin C; Cazenave JP; Gachet C Blood; 1998 Jul; 92(1):152-9. PubMed ID: 9639511 [TBL] [Abstract][Full Text] [Related]
11. Role of intracellular signaling events in ADP-induced platelet aggregation. Daniel JL; Dangelmaier C; Jin J; Kim YB; Kunapuli SP Thromb Haemost; 1999 Oct; 82(4):1322-6. PubMed ID: 10544922 [TBL] [Abstract][Full Text] [Related]
12. Effect of P2Y1 and P2Y12 genetic polymorphisms on the ADP-induced platelet aggregation in a Korean population. Kim KA; Song WG; Lee HM; Joo HJ; Park JY Thromb Res; 2013 Aug; 132(2):221-6. PubMed ID: 23849096 [TBL] [Abstract][Full Text] [Related]
13. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300 [TBL] [Abstract][Full Text] [Related]
14. [Suppressive effect in vitro of resveratrol on ADP induced human platelet aggregation and its active mechanism]. Yang YM; Wang XX; Wang SJ; Wang HQ; Chen JZ Yao Xue Xue Bao; 2008 Apr; 43(4):356-60. PubMed ID: 18664195 [TBL] [Abstract][Full Text] [Related]
15. Guanosine exerts antiplatelet and antithrombotic properties through an adenosine-related cAMP-PKA signaling. Fuentes F; Alarcón M; Badimon L; Fuentes M; Klotz KN; Vilahur G; Kachler S; Padró T; Palomo I; Fuentes E Int J Cardiol; 2017 Dec; 248():294-300. PubMed ID: 28811090 [TBL] [Abstract][Full Text] [Related]
16. In-vitro and ex-vivo inhibition of blood platelet aggregation by naftazone. Durand P; Bloy C; Peltier-Pujol F; Blache D J Pharm Pharmacol; 1996 Jun; 48(6):566-72. PubMed ID: 8832488 [TBL] [Abstract][Full Text] [Related]
17. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro. Weber AA; Reimann S; Schrör K Br J Pharmacol; 1999 Jan; 126(2):415-20. PubMed ID: 10077233 [TBL] [Abstract][Full Text] [Related]
18. Nucleoside triphosphates inhibit ADP, collagen, and epinephrine-induced platelet aggregation: role of P2Y₁ and P2Y₁₂ receptors. Aslam M; Sedding D; Koshty A; Santoso S; Schulz R; Hamm C; Gündüz D Thromb Res; 2013 Nov; 132(5):548-57. PubMed ID: 24071464 [TBL] [Abstract][Full Text] [Related]
19. Epinephrine restores platelet functions inhibited by ticagrelor: A mechanistic approach. Martin AC; Zlotnik D; Bonete GP; Baron E; Decouture B; Belleville-Rolland T; Le Bonniec B; Poirault-Chassac S; Alessi MC; Gaussem P; Godier A; Bachelot-Loza C Eur J Pharmacol; 2020 Jan; 866():172798. PubMed ID: 31738933 [TBL] [Abstract][Full Text] [Related]
20. cAMP is not an important messenger for ADP-induced platelet aggregation. Savi P; Pflieger AM; Herbert JM Blood Coagul Fibrinolysis; 1996 Mar; 7(2):249-52. PubMed ID: 8735831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]